𝔖 Bobbio Scriptorium

✦ LIBER ✦

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

✍ Scribed by William K. Oh; Matthew D. Galsky; Walter M. Stadler; Sandy Srinivas; Franklin Chu; Glenn Bubley; J. Goddard; Joi Dunbar; Robert W. Ross

Book ID: 116953644
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 353 KB
Volume: 78
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2011.04.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

570 POSTER Overcoming resistance to tyro

570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor

✍ G.D. Demetri; S. George; J.A. Morgan; A. van den Abbeele; M.T. Quigley; J.A. Fle 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

210 EML4-ALK is a sensitive client prote

210 EML4-ALK is a sensitive client protein of Hsp90, and rearrangements of the ALK locus are associated with clinical response to IPI-504 (retaspimycin hydrochloride), a novel Hsp90 chaperone inhibitor, in patients with non-small cell lung cancer

✍ C. Fritz; A. Lim; K. Slocum; C. Tunkey; G. Paez; K. West; R. Ross; E. Normant; L 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB